Approved Research This page provides a searchable list of all research protocols that have been reviewed and approved by the Uganda National Council for Science and Technology(UNCST).
Search By Approval Date:
Clear Filter Total: 6,033
Name Title Nationality Approval Date Expiry Date Field of Science/Classification Trial Type Research Type  
Samuel Kawuma
ID:
Facilitators and barriers to retention on Pre-exposure prophylaxis (PrEP) among Female Sex Workers attending Kiruddu National Referral Hospital.
REFNo: HS2771ES

1. To identify the implementation gaps along the Pre-Exposure Prophylaxis continuum of care and assess the factors associated factors with retention on PrEP among FSWs at Kiruddu National referral Hospital.,To design a stakeholder informed evidence-based intervention to improve retention on PrEP among FSWs at Kiruddu National Referral Hospital ,2. To determine the facilitators and barriers of retention on PrEP among FSWs in care at Kiruddu National referral Hospital.,
 Uganda 2023-04-12 14:43:04 2026-04-12 Medical and Health Sciences Non-Clinical Trial Non-degree Award
Francis Ssali
ID: UNCST-2021-R012134
 Protocol A5394: “Safety, Tolerability, and Impact of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants with both Chronic Hepatitis B and HIV” Version 1.0, May 27, 2022
REFNo: HS2647ES

1.2 Primary Objectives

1.2.1 To assess the safety and tolerability of treatment with SLGN administered once weekly by mouth for 24 weeks.

1.2.2 To determine the proportion of participants with ≥1 log10 IU/mL decline in quantitative HBsAg (qHBsAg) after SLGN treatment at Week 24.

1.3 Secondary Objectives

1.3.1 To determine the proportion of participants with ≥1 log10 IU/mL decline in qHBsAg at any time during the study after SLGN treatment initiation.

1.3.2 To determine the proportion of participants with ≥0.5 log10 IU/mL decline in qHBsAg after SLGN treatment at Week 24.

1.3.3 To determine the proportion of participants with ≥0.5 log10 IU/mL decline in qHBsAg at any time during the study after SLGN treatment initiation.

1.3.4 To evaluate the proportion of participants who achieve HBsAg loss after SLGN initiation and who sustain HBsAg loss during follow-up.

1.3.5 To evaluate changes in qHBsAg levels at Weeks 4, 12, 24, 36, and 48 after SLGN initiation and, separately, among the placebo recipients.

1.3.6 To determine the proportion of HBeAg positive participants at baseline who lose HBeAg at any time during the study, by study arm.

1.3.7 To determine the proportion of anti-HBe negative participants at baseline who develop anti-HBe at any time during the study, by study arm.

1.3.8 To determine the proportion of hepatitis B surface antibody (anti-HBs) negative participants at baseline who develop anti-HBs at any time during the study, by study arm.
1.3.9 To evaluate levels of circulating cytokines, including IFN-gamma, IL-12p40, IL-1RA, and CD163 at entry, 24 hours post-first study drug dose, Weeks 4, 12, 24, 36, and 48, by study arm.

1.3.10 To determine whether administration of SLGN will perturb HIV latency as measured by an increase in HIV transcription.

1.3.11 To determine whether administration of SLGN will decrease the size of the latent reservoir, as measured by the change in amount of cell-associated unspliced HIV RNA, HIV DNA, replication-competent and/or intact virus at Weeks 2, 4, 24, and 48.

1.4 Exploratory Objectives

1.4.1 To define the pharmacokinetic (PK) profile and PK-pharmacodynamic (PD) associations of SLGN in people with both HIV and CHB taking suppressive antiviral therapy for both viruses.

1.4.2 To explore if SLGN and antiretroviral (ARV) PK are altered when administered together.

1.4.3 To evaluate participants’ adherence by using several tools, including self-report, directly observed therapy (DOT), and drug concentrations.

1.4.4 To compare quantitative changes in experimental measures of HBV antiviral efficacy (including HBV RNA, hepatitis B core related antigen [HBcrAg], qHBeAg, and low positive HBsAg measured with a high sensitivity qHBsAg assay [LLOQ of 0.05 IU/mL]) and measure changes in large, medium, and small HBsAg isoforms from baseline during and after treatment.

1.4.5 To determine the immunological effects of SLGN on circulating immune signaling by performing single cell RNA sequencing using peripheral blood mononuclear cells (PBMCs) and evaluating HIV-specific T-cell responses.

1.4.6 To determine the effects on circulating immune cells, including cellular phenotypes and T and B-cell responses.

1.4.7 To determine whether administration of SLGN will affect levels of circulating cytokines, including TNF-alpha, IL-12, IL18, IP-10, ISG15, IL-21, Fas Ligand, and TRAIL.

 Uganda 2023-04-12 14:38:49 2026-04-12 Medical and Health Sciences Clinical Trial Non-degree Award
Alex Mwesigwa
ID:
P. falciparum genetic diversity, multiplicity of infection, gametocytaemia and recrudescence in areas of varied malaria transmission intensity in Uganda.
REFNo: HS2744ES

1. To compare the genetic diversity and multiplicity of P. falciparum infections in areas of varied malaria transmission intensity in Uganda.
2. To evaluate the relationship between malaria severity and P. falciparum genetic diversity, multiplicity of infection among patients living in areas of varied malaria transmission intensity in Uganda.
3. To investigate the temporal and seasonality changes in P. falciparum genetic diversity and multiplicity of infection among patients with malaria infection living in areas of varied malaria transmission intensity in Uganda.
4. To evaluate the performance of microsatellites in differentiating P. falciparum recrudescence from new infections.

 Uganda 2023-04-12 14:27:32 2026-04-12 Medical and Health Sciences Non-Clinical Trial Degree Award
Jane Frances Zalwango
ID:
Etiopathogenesis of Blackwater Fever in Budaka District, Uganda: a pilot study
REFNo: HS2752ES

a)To explore the aetiology of BWF in Budaka District b)To identify therapeutic interventions for the treatment of BWF
Uganda 2023-04-12 14:23:40 2026-04-12 Medical and Health Sciences Non-Clinical Trial Non-degree Award
Elizeus Rutebemberwa
ID: UNCST-2022-R009070
 Evaluation of a Community Health Entrepreneur model in rural Uganda
REFNo: HS2196ES

4.3 General objective
To explore the role, reach, and scalability of CHE programme as a social franchise approach to address the issue of access to healthcare and potential embedment of the programme in the larger health system.

4.4 Specific objectives
1. To investigate health care seeking behaviour of residents in rural communities in Uganda, in order to assess community access, choice and use of health (care) services, service availability and quality, and experience of health care of households in villages in Uganda
2. To investigate the strengths and weaknesses of a CHE programme in communities which already have adopted this programme and the potential added value of a strengthened community health system by a CHE programme in communities without this programme
3. To investigate multi-stakeholder perceptions on the functioning, potential scale-up, and the possibility of integration of a social franchise approach in the larger health system in Uganda


 Uganda 2023-04-12 14:20:54 2026-04-12 Medical and Health Sciences Non-Clinical Trial Non-degree Award
View Sort By:

"A prosperous Science and Technology Led Ugandan Society."

NRIMS